@bgr.com 3 months ago
This groundbreaking new coronavirus cure is unlike any other drug we’ve seen so far
@xconomy.com 3 months ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com 4 months ago
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
@xconomy.com 4 months ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com 4 months ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com 5 months ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com 6 months ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com 11 months ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com 11 months ago
CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019
@xconomy.com 1 year ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com 1 year ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com 1 year ago
Venture Investors Bets on Healthcare, and Milwaukee, With $75M Fund
@xconomy.com 1 year ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com 1 year ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@xconomy.com 1 year ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com 1 year ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com 1 year ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@techcrunch.com 1 year ago
Only 2% of genomic material available for research comes from Africa, 54gene wants to change that
@xconomy.com 1 year ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com 1 year ago
Meet the Xconomy Awards San Diego Digital Trailblazer Finalists
@techcrunch.com 1 year ago
Healthcare by 2028 will be doctor-directed, patient-owned and powered by visual technologies
@xconomy.com 1 year ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com 2 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com 2 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com 2 years ago
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More
@xconomy.com 2 years ago
ESMO ’18: Precision Meds, Breast, Lung, and More from the Cancer Front
@xconomy.com 2 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine
@xconomy.com 2 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More